Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer

Abstract excerpt

BACKGROUND: )-mutant non-small-cell lung cancer (NSCLC). Zongertinib is an oral, irreversible, HER2-selective tyrosine kinase inhibitor that has been shown to have efficacy in persons with advanced or metastatic solid tumors with HER2 alterations in a phase 1 study. METHODS: -mutant NSCLC. Here we report the primary analysis of zongertinib in previously treated patients: those with tumors harboring a mutation in...

Topics

Join the communities discussing this publication.

• HER2/EGFR in Cancer Research
• Lung Cancer Research Studies
• Lung Cancer Treatments and Mutations